These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 12827614)
21. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870 [TBL] [Abstract][Full Text] [Related]
22. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer. Kim NY; Pyo JS Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757 [TBL] [Abstract][Full Text] [Related]
23. Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Berghmans T; Mascaux C; Martin B; Ninane V; Sculier JP Lung Cancer; 2006 May; 52(2):219-24. PubMed ID: 16545887 [TBL] [Abstract][Full Text] [Related]
24. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Feng J; Zhang X; Zhu H; Wang X; Ni S; Huang J Am J Clin Pathol; 2012 Aug; 138(2):230-5. PubMed ID: 22904134 [TBL] [Abstract][Full Text] [Related]
25. IMP3 can predict aggressive behaviour of lung adenocarcinoma. Beljan Perak R; Durdov MG; Capkun V; Ivcevic V; Pavlovic A; Soljic V; Peric M Diagn Pathol; 2012 Nov; 7():165. PubMed ID: 23190601 [TBL] [Abstract][Full Text] [Related]
26. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781 [TBL] [Abstract][Full Text] [Related]
27. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106 [TBL] [Abstract][Full Text] [Related]
28. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Bejarano PA; Baughman RP; Biddinger PW; Miller MA; Fenoglio-Preiser C; al-Kafaji B; Di Lauro R; Whitsett JA Mod Pathol; 1996 Apr; 9(4):445-52. PubMed ID: 8729987 [TBL] [Abstract][Full Text] [Related]
30. Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC. Sun R; Liu Z; Ma G; Lv W; Zhao X; Lei G; Xu C Int J Clin Exp Pathol; 2015; 8(3):2392-9. PubMed ID: 26045746 [TBL] [Abstract][Full Text] [Related]
31. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Chang YL; Lee YC; Liao WY; Wu CT Lung Cancer; 2004 May; 44(2):149-57. PubMed ID: 15084379 [TBL] [Abstract][Full Text] [Related]
32. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Mukhopadhyay S; Katzenstein AL Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283 [TBL] [Abstract][Full Text] [Related]
33. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470 [TBL] [Abstract][Full Text] [Related]
34. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer. Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190 [TBL] [Abstract][Full Text] [Related]
35. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis. Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891 [TBL] [Abstract][Full Text] [Related]
36. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer. Xu XY; Lin N; Li YM; Zhi C; Shen H Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236 [TBL] [Abstract][Full Text] [Related]
37. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers. Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820 [TBL] [Abstract][Full Text] [Related]
38. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026 [TBL] [Abstract][Full Text] [Related]
39. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: analysis of 427 cases. Anton RC; Brown RW; Younes M; Gondo MM; Stephenson MA; Cagle PT Hum Pathol; 1997 Sep; 28(9):1079-82. PubMed ID: 9308733 [TBL] [Abstract][Full Text] [Related]
40. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. Anagnostou VK; Lowery FJ; Zolota V; Tzelepi V; Gopinath A; Liceaga C; Panagopoulos N; Frangia K; Tanoue L; Boffa D; Gettinger S; Detterbeck F; Homer RJ; Dougenis D; Rimm DL; Syrigos KN BMC Cancer; 2010 May; 10():186. PubMed ID: 20459695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]